CMS certification 223302
Boston Children's Hospital
300 Longwood Avenue, Boston, MA 02115
This page brings together federal quality data for this hospital: its CMS star rating, patient survey results, emergency department times, and death, complication, infection and readmission rates, each compared with the national rate. Everything here comes from CMS and NPPES, the federal sources themselves - not from us.
What patients said
Answers from patients who stayed here, collected by CMS in the national HCAHPS survey: Oct 2024 – Sep 2025.
Not reported for this hospital
CMS had too few cases here to publish results for deaths, complications, infections caught in the hospital, readmissions and return visits. That is common at small, rural and specialty hospitals, and says nothing either way about quality.
Clinicians registered at this address
3,739 clinicians give this hospital's street address as their practice location in NPPES, the federal provider registry, plus 360 residents and trainees. The same address can take in offices and clinics in the building, and a listing does not prove admitting privileges or current employment.
| Specialty | Clinicians |
|---|---|
| Pediatrics | 857 |
| Clinical | 323 |
| Family | 216 |
| Physician Assistant | 173 |
| Neurology with Special Qualifications in Child Neurology | 99 |
| Pediatric Cardiology | 91 |
| Pediatric Critical Care Medicine | 85 |
| Pediatric Gastroenterology | 77 |
| Physical Therapist | 77 |
| Pediatric Emergency Medicine | 73 |
| Anesthesiology | 70 |
| Pediatric Anesthesiology | 56 |
First 12 alphabetically
Money from drug and device companies
Drug and device makers have to report what they pay teaching hospitals to CMS's Open Payments program. At many teaching hospitals most of it is research funding, or royalties for inventions the hospital licensed to a company. A payment on its own does not show a conflict of interest.
- 2019 $16.9M
- 2020 $18.4M
- 2021 $20.3M
- 2022 $17M
- 2023 $24.6M
- 2024 $35.4M
- 2025 $28.8M
What the 2025 general payments were for
| Type of payment | Amount | Payments |
|---|---|---|
| Royalties and licensing fees | $11.1M | 87 |
| Charitable contributions | $897,105 | 78 |
| Grants | $592,552 | 29 |
| Speaking, teaching and other services | $117,101 | 4 |
| Consulting fees | $100,000 | 1 |
| Space rental and facility fees | $65,000 | 9 |
| Debt forgiveness | $13,430 | 14 |
| Education | $13,000 | 3 |
| Gifts | $10,000 | 1 |
| Medical devices and supplies on long-term loan | $1,124 | 5 |
| Food and beverage | $123 | 1 |
Largest paying companies, 2025
| Company | Amount | Payments |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $9.1M | 24 |
| E.R. Squibb & Sons, L.L.C. | $3M | 7 |
| Pfizer INC. | $2.7M | 32 |
| Vertex Pharmaceuticals Incorporated | $1.7M | 12 |
| Fresenius Kabi USA, LLC | $1.1M | 4 |
| Ultragenyx Pharmaceutical Inc. | $988,236 | 64 |
| Miach Orthopaedics, Inc. | $877,566 | 2 |
| Merck Sharp & Dohme LLC | $724,160 | 4 |
Largest research studies funded here, 2025
| Study | Amount |
|---|---|
| A RANDOMIZED DOUBLE-BLIND TRIAL OF ABATACEPT EXTENDED DOSING VERSUS ABATACEPT SHORT-TERM DOSING FOR GRAFT VERSUS HOST DISEASE PROPHYLAXIS: ABA3 E.R. Squibb & Sons, L.L.C. | $2.2M |
| FACTORS ASSOCIATED WITH TIME TO SYMPTOM RESOLUTION IN CHILDREN WITH LYME DISEASE PFIZER INC. | $1.4M |
| LOW INTERVENTIONAL COHORT STUDY OF MYOCARDITISPERICARDITIS ASSOCIATED WITH COMIRNATY IN PERSONS LESS THAN 21 YEARS OF AGE PFIZER INC. | $830,963 |
| A Rheumatoid Arthritis Study to Assess Early Response to Abatacept+MTX as Defined by Improvement of Synovitis Measures by Power Doppler Ultrasonograp… E.R. Squibb & Sons, L.L.C. · NCT00767325 | $653,905 |
| GTX-102-CL301 Ultragenyx Pharmaceutical Inc. · NCT06617429 | $469,024 |
| A Phase 1 Single Dose Escalation Study Evaluating the Safety and Tolerability of VX-522 in Subjects 18 Years of Age and Older With Cystic Fibrosis an… VERTEX PHARMACEUTICALS INCORPORATED | $422,209 |
| A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis VERTEX PHARMACEUTICALS INCORPORATED | $417,708 |
| GTX-102-CL302 Ultragenyx Pharmaceutical Inc. · NCT06415344 | $402,152 |
Amounts are as the paying companies reported them to CMS; Open Payments data retrieved 13 Sep 2026. Full record on CMS Open Payments.
How to read this page
- Everything here is published by CMS on Care Compare. We arrange it and explain it; the star ratings and the better / worse verdicts are CMS's, not ours.
- “No different” is the most common result on most measures at most hospitals. CMS only calls a result better or worse when the difference from the national rate is statistically clear.
- Death, complication and readmission rates are adjusted by CMS for how sick patients were, so hospitals that treat sicker patients can be compared fairly.
- Infection results are ratios: 1.0 means as many infections as CMS predicted for a hospital like this one, below 1.0 is fewer.
- These are hospital-wide results. They do not rate an individual doctor, nurse or department, and they are not medical advice.
CMS Care Compare data retrieved 4 Oct 2026, refreshed weekly. Where this data comes from and how we handle it · Report an error
Common questions about Boston Children's Hospital
Does Boston Children's Hospital have an emergency room?
Yes. CMS lists emergency services at Boston Children's Hospital.
Does Boston Children's Hospital receive money from drug and device companies?
Drug and device makers reported $28.8M in payments to Boston Children's Hospital for 2025, most of it research funding, under the federal Open Payments program. A payment on its own does not show a conflict of interest.